Yahoo Finance

• Total Revenue (Q4 2024): $1.28 billion, reflecting 11% growth.

• Total Revenue (Full Year 2024): $4.791 billion, reflecting 17% growth.

• Vision Care Revenue (Q4 2024): $723 million, increased by 11%.

• Vision Care Revenue (Full Year 2024): $2.739 billion, increased by 10%.

• Surgical Segment Revenue (Q4 2024): $231 million, increased by 15%.

• Surgical Segment Revenue (Full Year 2024): $843 million, increased by 11%.

• Pharma Segment Revenue (Q4 2024): $326 million, increased by 7%.

• Pharma Segment Revenue (Full Year 2024): $1.209 billion, increased by 45%.

• Adjusted Gross Margin (Q4 2024): 62.5%.

• Adjusted Gross Margin (Full Year 2024): 62.6%, up 160 basis points from last year.

• Adjusted EBITDA (Q4 2024): $259 million, 14% growth versus Q4 2023.

• Adjusted EBITDA (Full Year 2024): $878 million, up 20% versus 2023.

• Adjusted Cash Flow from Operations (Full Year 2024): $263 million, compared to $56 million in 2023.

• 2025 Revenue Guidance: $4.95 billion to $5.05 billion, reflecting 5.5% to 7.5% constant currency growth.

• 2025 Adjusted EBITDA Guidance: $900 million to $950 million.

• Warning! GuruFocus has detected 5 Warning Signs with BLCO.

Release Date: February 19, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Bausch & Lomb Corp (NYSE:BLCO) achieved its fifth consecutive quarter of double-digit constant currency revenue growth, contributing to a 17% growth for the year.

• The company has successfully introduced new products across various geographies and optimized its manufacturing processes, including the deployment of AI.

• BLCO's R&D organization has been overhauled, leading to a promising pipeline filled with innovative products, such as a first-of-its-kind Biomimetic contact lens.

• The company's dry eye portfolio is nearing $1 billion in annual revenue, with significant contributions from products like Miebo and Xiidra.

• BLCO's contact lens segment reported strong growth, with daily SiHy lenses achieving over 70% revenue growth for the year.

Negative Points

• The company faces currency headwinds, which impacted revenue by $69 million and adjusted EBITDA by $11 million for the full year.

• BLCO anticipates a $25 million impact from the Inflation Reduction Act in 2025, affecting adjusted gross margin.

• The company is investing heavily in R&D and direct-to-consumer campaigns, which may impact short-term profitability.

• BLCO's guidance for 2025 reflects a slowdown in revenue growth to 5.5% to 7.5%, compared to the previous year's 17% growth.

• The company is absorbing a $20 million impact related to the recent acquisition of Elios, which may affect short-term financial performance.